New 20aqueduct 20csf 20logo 20final 20white 20space
New 20aqueduct 20csf 20logo 20final 20white 20space 20without 20circles

Aqueduct Critical Care, Inc

Aqueduct Critical Care is commercializing their SMART EXTERNAL DRAIN (SED) to revolutionize the way patients with CSF drains are managed.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Bothell, WA, USA
  • Currency USD
  • Founded May 2013
  • Employees 14
  • Incorporation Type C-corp
  • Website aqueductcriticalcare.com

Company Summary

Aqueduct is commercializing technology that will become the standard of care for cerebrospinal fluid (CSF) drainage and intracranial pressure (ICP) monitoring. Aqueduct’s innovation will increase patient safety while improving staff and critical care unit efficiencies. Patients will benefit from increased mobility.

Team

  • Default avatar
    Tom Clement
    President / CEO

    Mr. Clement is a seasoned medical device veteran with 30+ years’ experience in the industry including as CEO of start-ups Pathway Medical and Cardiac Insight. Mr. Clement is responsible for bringing multiple medical devices to market over his career spanning Neurosurgery, Interventional Cardiology, Vascular Surgery, Gasteroenterology and Radiology.

  • Default avatar
    Samuel Browd
    Chief Medical Officer

    Samuel Browd, MD, PhD is Assistant Professor of Neurological Surgery at the University of Washington and attending pediatric neurosurgeon at Seattle Children's Hospital. Dr. Browd performs over 100 operations / yr to treat hydrocephalus. He focuses on research of hydrocephalus. Dr. Browd is the lead site investigator for the Hydrocephalus Clinical Research Network (HCRN) at the UW and the Director of the Hydrocephalus Program at SCH.

  • Default avatar
    Barry Lutz
    Chief Technology Officer

    Dr. Lutz is an Assistant Professor of Bioengineering at the University of Washington. He is an expert in microfluidic systems for biotechnology applications with expertise in medical diagnostics and devices to treat hydrocephalus. His projects have a translational focus, and generally address commercialization issues. He develops technology directed at identified problems and approaches that can be successfully translated to patients.

  • B70cf0b6 de48 49b8 9525 b5a00e994513
    Business Development

    Ms. Amoss has 24+ years in the medical device industry, most recently as a consultant to small & mid-size companies. Previously, she served as SVP, Marketing & Strategic Development at Pathway Medical, and in multiple leadership roles with Spiration and ACS (Guidant). Ms. Amoss’ broad range of global management roles in market development, clinical trials, regulatory, and reimbursement makes her particularly valuable to early stage companies.

Advisors

  • Default avatar
    Sonya Erickson
    Lawyer
    Unconfirmed

Previous Investors